Oxidative stress in chronic kidney disease

Iranian Journal of Kidney Diseases

Volumn 9, Issue 3, 2015, Pages 165-179

  Modaresi, Atieh ^a   Nafar, Mohsen ^b,c   Sahraei, Zahra ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Antioxidants; Biomarkers; Chronic kidney disease; Oxidative stress

Indexed keywords

8 ISOPROSTAGLANDIN F2 ALPHA; ACETYLCYSTEINE; ADVANCED GLYCATION END PRODUCT; ADVANCED OXIDATION PROTEIN PRODUCT; ALPHA TOCOPHEROL; ARACHIDONIC ACID; ASCORBIC ACID; BETA CAROTENE; C REACTIVE PROTEIN; CARNITINE; CATALASE; ENDOTOXIN; FIBRINOGEN; FOLIC ACID; GLUTATHIONE PEROXIDASE; GLUTATHIONE TRANSFERASE; HAPTOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NUCLEIC ACID; OMEGA 3 FATTY ACID; REACTIVE OXYGEN METABOLITE; SERUM ALBUMIN; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TUMOR NECROSIS FACTOR ALPHA; UBIDECARENONE; UBIQUINONE; UNINDEXED DRUG; UREMIC TOXIN; ANTIOXIDANT; BIOLOGICAL MARKER;

ARTICLE; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DYSLIPIDEMIA; END STAGE RENAL DISEASE; ERYTHROCYTE; GENETIC POLYMORPHISM; GLUCOSE BLOOD LEVEL; HEMODIALYSIS; HUMAN; HYPERTENSION; INFLAMMATION; IRON THERAPY; KIDNEY TRANSPLANTATION; LIPID PEROXIDATION; NONHUMAN; OXIDATIVE STRESS; RENAL REPLACEMENT THERAPY; RESPIRATORY SYSTEM; SYSTEMATIC REVIEW (TOPIC); UREMIA; BLOOD; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; COMPLICATION; DISEASE COURSE; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; OXIDATION REDUCTION REACTION; RISK FACTOR;

ANTIOXIDANTS; BIOMARKERS; CARDIOVASCULAR DISEASES; DISEASE PROGRESSION; HUMANS; INFLAMMATION; KIDNEY FAILURE, CHRONIC; OXIDATION-REDUCTION; OXIDATIVE STRESS; RISK FACTORS; UREMIA;

EID: 84928981822     PISSN: 17358582     EISSN: 17358604     Source Type: Journal    
DOI: None     Document Type: Article

References (142)

1. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998;32:S112-9.
2. Kao MP, Ang DS, Pall A, Struthers AD. Oxidative stress in renal dysfunction: mechanisms, clinical sequelae and therapeutic options. J Hum Hypertens. 2010;24:1-8.
3. Bai Y, Sigala W, Adams GR, Vaziri ND. Effect of exercise on cardiac tissue oxidative and inflammatory mediators in chronic kidney disease. Am J Nephrol. 2009;29:213-21.
4. Himmelfarb J. Linking oxidative stress and inflammation in kidney disease: which is the chicken and which is the egg. Semin Dial. 2004;17:449-54.
5. Nafar M, Sahraei Z, Salamzadeh J, Samavat S, Vaziri ND. Oxidative stress in kidney transplantation: causes, consequences, and potential treatment. Iran J Kidney Dis. 2011;5:357-72.
6. Locatelli F, Canaud B, Eckardt KU, Stenvinkel P, Wanner C, Zoccali C. Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant. 2003;18:1272-80.
7. Descamps-Latscha B, Drueke T, Witko-Sarsat V. Dialysisinduced oxidative stress: biological aspects, clinical consequences, and therapy. Semin Dial. 2001;14:193-9.
8. Granata S, Zaza G, Simone S, et al. Mitochondrial dysregulation and oxidative stress in patients with chronic kidney disease. BMC Genomics. 2009;10:388.
9. Suvakov S, Damjanovic T, Stefanovic A, et al. Glutathione S-transferase A1, M1, P1 and T1 null or low-activity genotypes are associated with enhanced oxidative damage among haemodialysis patients. Nephrol Dial Transplant. 2013;28:202-12.
10. Vostalova J, Galandakova A, Svobodova AR, et al. Timecourse evaluation of oxidative stress-related biomarkers after renal transplantation. Ren Fail. 2012;34:413-9.
11. Ceballos-Picot I, Witko-Sarsat V, Merad-Boudia M, et al. Glutathione antioxidant system as a marker of oxidative stress in chronic renal failure. Free Radic Biol Med. 1996;21:845-53.
12. Canaud B, Cristol J, Morena M, Leray-Moragues H, Bosc J, Vaussenat F. Imbalance of oxidants and antioxidants in haemodialysis patients. Blood Purif. 1999;17:99-106.
13. Morena M, Delbosc S, Dupuy AM, Canaud B, Cristol JP. Overproduction of reactive oxygen species in endstage renal disease patients: a potential component of hemodialysis-associated inflammation. Hemodial Int. 2005;9:37-46.
14. Becker BN, Himmelfarb J, Henrich WL, Hakim RM. Reassessing the cardiac risk profile in chronic hemodialysis patients: a hypothesis on the role of oxidant stress and other non-traditional cardiac risk factors. J Am Soc Nephrol. 1997;8:475-86.
15. Descamps-Latscha B, Witko-Sarsat V. [Oxidative stress in chronic renal failure and hemodialysis]. Nephrologie. 2003;24:377-9. French.
16. Tarng DC, Huang TP, Wei YH, et al. 8-hydroxy-2’-deoxyguanosine of leukocyte DNA as a marker of oxidative stress in chronic hemodialysis patients. Am J Kidney Dis. 2000;36:934-44.
17. Drueke T, Witko-Sarsat V, Massy Z, et al. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation. 2002;106:2212-7.
18. Pawlak K, Pawlak D, Mysliwiec M. Long-term erythropoietin therapy does not affect endothelial markers, coagulation activation and oxidative stress in haemodialyzed patients. Thromb Res. 2007;120:797-803.
19. Koca T, Berber A, Koca HB, Demir TA, Koken T. Effects of hemodialysis period on levels of blood trace elements and oxidative stress. Clin Exp Nephrol. 2010;14:463-8.
20. Sozer V, Korkmaz Guntas G, Konukoglu D, et al. Effects of peritoneal-and hemodialysis on levels of plasma protein and lipid oxidation markers in diabetic patients. Minerva Med. 2013;104:75-84.
21. Filiopoulos V, Hadjiyannakos D, Takouli L, Metaxaki P, Sideris V, Vlassopoulos D. Inflammation and oxidative stress in end-stage renal disease patients treated with hemodialysis or peritoneal dialysis. Int J Artif Organs. 2009;32:872-82.
22. Mehmetoglu I, Yerlikaya FH, Kurban S, Erdem SS, Tonbul Z. Oxidative stress markers in hemodialysis and peritoneal dialysis patients, including coenzyme Q10 and ischemiamodified albumin. Int J Artif Organs. 2012;35:226-32.
23. Aveles PR, Criminacio CR, Goncalves S, et al. Association between biomarkers of carbonyl stress with increased systemic inflammatory response in different stages of chronic kidney disease and after renal transplantation. Nephron Clin Pract. 2010;116:c294-9.
24. Kuchta A, Pacanis A, Kortas-Stempak B, et al. Estimation of oxidative stress markers in chronic kidney disease. Kidney Blood Press Res. 2011;34:12-9.
25. Pupim LB, Himmelfarb J, McMonagle E, Shyr Y, Ikizler TA. Influence of initiation of maintenance hemodialysis on biomarkers of inflammation and oxidative stress. Kidney Int. 2004;65:2371-9.
26. Yildiz G, Aydin H, Magden K, Yilmaz A, Hur E, Candan F. Influence of single hemodialysis session on serum paraoxonase-1, arylesterase activity, total oxidant status and total antioxidant status. Minerva Med. 2014;105:79-87.
27. Zanetti M, Barazzoni R, Gortan Cappellari G, et al. Hemodialysis induces p66(shc) gene expression in nondiabetic humans: correlations with oxidative stress and systemic inflammation. J Ren Nutr. 2011;21:401-9.
28. Forbes JM, Coughlan MT, Cooper ME. Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes. 2008;57:1446-54.
29. Kashihara N, Haruna Y, Kondeti VK, Kanwar YS. Oxidative stress in diabetic nephropathy. Curr Med Chem. 2010;17:4256-69.
30. Goh SY, Cooper ME. Clinical review: the role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab. 2008;93:1143-52.
31. Vaziri ND. Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol. 2006;290:F262-72.
32. Zalba G, Fortuno A, Diez J. Oxidative stress and atherosclerosis in early chronic kidney disease. Nephrol Dial Transplant. 2006;21:2686-90.
33. Pawlak K, Pawlak D, Mysliwiec M. [Method of dialysis therapy and selected markers of oxidative stress and endothelial injury in patients with chronic renal failure]. Pol Arch Med Wewn. 2005;113:21-6. Polish.
34. Simmons EM, Langone A, Sezer MT, et al. Effect of renal transplantation on biomarkers of inflammation and oxidative stress in end-stage renal disease patients. Transplantation. 2005;79:914-9.
35. Annuk M, Soveri I, Zilmer M, Lind L, Hulthe J, Fellstrom B. Endothelial function, CRP and oxidative stress in chronic kidney disease. J Nephrol. 2005;18:721-6.
36. Oberg BP, McMenamin E, Lucas FL, et al. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int. 2004;65:1009-16.
37. Dummer CD, Thome FS, Zingano B, Lindoso A, Veronese FV. Acute effect of simvastatin on inflammation and oxidative stress in chronic kidney disease. J Nephrol. 2008;21:900-8.
38. Handelman GJ. Evaluation of oxidant stress in dialysis patients. Blood Purif. 2000;18:343-9.
39. Tucker PS, Dalbo VJ, Han T, Kingsley MI. Clinical and research markers of oxidative stress in chronic kidney disease. Biomarkers. 2013;18:103-15.
40. Atamer A, Kocyigit Y, Ecder SA, et al. Effect of oxidative stress on antioxidant enzyme activities, homocysteine and lipoproteins in chronic kidney disease. J Nephrol. 2008;21:924-30.
41. Martin-Mateo MC, Sanchez-Portugal M, Iglesias S, de Paula A, Bustamante J. Oxidative stress in chronic renal failure. Ren Fail. 1999;21;155-67.
42. Kaya Y, Ari E, Demir H, et al. Accelerated atherosclerosis in haemodialysis patients;correlation of endothelial function with oxidative DNA damage. Nephrol Dial Transplant. 2012;27:1164-9.
43. Boaz M, Matas Z, Biro A, et al. Serum malondialdehyde and prevalent cardiovascular disease in hemodialysis. Kidney Int. 1999;56:1078-83.
44. Peuchant E, Carbonneau MA, Dubourg L, et al. Lipoperoxidation in plasma and red blood cells of patients undergoing haemodialysis: vitamins A, E, and iron status. Free Radic Biol Med. 1994;16:339-46.
45. Ari E, Kaya Y, Demir H, et al. Oxidative DNA damage correlates with carotid artery atherosclerosis in hemodialysis patients. Hemodial Int. 2011;15:453-9.
46. Lucchi L, Iannone A, Bergamini S, et al. Comparison between hydroperoxides and malondialdehyde as markers of acute oxidative injury during hemodialysis. Artif Organs. 2005;29:832-7.
47. Palleschi S, De Angelis S, Diana L, et al. Reliability of oxidative stress biomarkers in hemodialysis patients: a comparative study. Clin Chem Lab Med. 2007;45:1211-8.
48. Ho E, Karimi Galougahi K, Liu CC, Bhindi R, Figtree GA. Biological markers of oxidative stress: applications to cardiovascular research and practice. Redox Biol. 2013;1:483-91.
49. Diepeveen SH, Verhoeven GH, van der Palen J, et al. Oxidative stress in patients with end-stage renal disease prior to the start of renal replacement therapy. Nephron Clin Pract. 2004;98:c3-7.
50. Cvetkovic T, Mitic B, Lazarevic G, Vlahovic P, Antic S, Stefanovic V. Oxidative stress parameters as possible urine markers in patients with diabetic nephropathy. J Diabetes Complications. 2009;23:337-42.
51. Kocak H, Gumuslu S, Ermis C, et al. Oxidative stress and asymmetric dimethylarginine is independently associated with carotid intima media thickness in peritoneal dialysis patients. Am J Nephrol. 2008;28:91-6.
52. Lim PS, Chang YM, Thien LM, et al. 8-iso-prostaglandin F2alpha as a useful clinical biomarker of oxidative stress in ESRD patients. Blood Purif. 2002;20:537-42.
53. Handelman GJ, Walter MF, Adhikarla R, et al. Elevated plasma F2-isoprostanes in patients on long-term hemodialysis. Kidney Int. 2001;59:1960-6.
54. Namiduru ES, Tarakcioglu M, Tiryaki O, Usalan C. Evaluation of oxidative and nitrosative stress in hemodialysis patients. Minerva Med. 2010;101:305-10.
55. Witko-Sarsat V, Nguyen-Khoa T, Jungers P, Drueke TB, Descamps-Latscha B. Advanced oxidation protein products as a novel molecular basis of oxidative stress in uraemia. Nephrol Dial Transplant. 1999;14:76-8.
56. Zhou Q, Wu S, Jiang J, et al. Accumulation of circulating advanced oxidation protein products is an independent risk factor for ischaemic heart disease in maintenance haemodialysis patients. Nephrology (Carlton). 2012;17:642-9
57. Witko-Sarsat V, Descamps-Latscha B. Advanced oxidation protein products: novel uraemic toxins and proinflammatory mediators in chronic renal failure? Nephrol Dial Transplant. 1997;12:1310-2.
58. Yang XB, Hou FF, Wu Q, et al. [Increased levels of advanced oxidation protein products are associated with atherosclerosis in chronic kidney disease]. Zhonghua Nei Ke Za Zhi. 2005;44:342-6. Chinese.
59. Rodriguez-Ayala E, Anderstam B, Suliman ME, et al. Enhanced RAGE-mediated NFkappaB stimulation in inflamed hemodialysis patients. Atherosclerosis. 2005;180:333-40.
60. Dalle-Donne I, Rossi R, Giustarini D, Milzani A, Colombo R. Protein carbonyl groups as biomarkers of oxidative stress. Clin Chim Acta. 2003;329:23-38.
61. Mitrogianni Z, Barbouti A, Galaris D, Siamopoulos KC. Oxidative modification of albumin in predialysis, hemodialysis, and peritoneal dialysis patients. Nephron Clin Pract. 2009;113:c234-40.
62. Tarng DC, Wen Chen T, Huang TP, Chen CL, Liu TY, Wei YH. Increased oxidative damage to peripheral blood leukocyte DNA in chronic peritoneal dialysis patients. J Am Soc Nephrol. 2002;13:1321-30.
63. Coaccioli S, Standoli ML, Biondi R, et al. Open comparison study of oxidative stress markers between patients with chronic renal failure in conservative therapy and patients in haemodialysis. Clin Ter. 2010;161:435-9.
64. Bergesio F, Monzani G, Ciuti R, et al. Total antioxidant capacity (TAC): is it an effective method to evaluate the oxidative stress in uraemia? J Biolumin Chemilumin. 1998;13:315-9.
65. Roehrs M, Valentini J, Paniz C, et al. The relationships between exogenous and endogenous antioxidants with the lipid profile and oxidative damage in hemodialysis patients. BMC Nephrol. 2011;12:59-71.
66. El-Far MA, Bakr MA, Farahat SE, Abd El-Fattah EA. Glutathione peroxidase activity in patients with renal disorders. Clin Exp Nephrol. 2005;9:127-31.
67. Annuk M, Fellstrom B, Akerblom O, Zilmer K, Vihalemm T, Zilmer M. Oxidative stress markers in pre-uremic patients. Clin Nephrol. 2001;56:308-14.
68. Pawlak K, Pawlak D, Mysliwiec M. Cu/Zn superoxide dismutase plasma levels as a new useful clinical biomarker of oxidative stress in patients with end-stage renal disease. Clin Biochem. 2005;38:700-5.
69. Pawlak K, Mysliwiec M, Pawlak D. Oxidative stress, phosphate and creatinine levels are independently associated with vascular endothelial growth factor levels in patients with chronic renal failure. Cytokine. 2008;43:98-101.
70. Johnson-Davis KL, Fernelius C, Eliason NB, Wilson A, Beddhu S, Roberts WL. Blood enzymes and oxidative stress in chronic kidney disease: a cross sectional study. Ann Clin Lab Sci. 2011;41:331-9.
71. Postorino M, Marino C, Tripepi G, Zoccali C. Gammaglutamyltransferase in ESRD as a predictor of all-cause and cardiovascular mortality: another facet of oxidative stress burden. Kidney Int Suppl. 2008;111:S64-6.
72. Santangelo F, Witko-Sarsat V, Drueke T, Descamps-Latscha B. Restoring glutathione as a therapeutic strategy in chronic kidney disease. Nephrol Dial Transplant. 2004;19:1951-5.
73. Lim PS, Chan EC, Lu TC, et al. Lipophilic antioxidants and iron status in ESRD patients on hemodialysis. Nephron. 2000;86:428-35.
74. Wang S, Eide TC, Sogn EM, Berg KJ, Sund RB. Plasma ascorbic acid in patients undergoing chronic haemodialysis. Eur J Clin Pharmacol. 1999;55:527-32.
75. Deicher R, Ziai F, Bieglmayer C, Schillinger M, Horl WH. Low total vitamin C plasma level is a risk factor for cardiovascular morbidity and mortality in hemodialysis patients. J Am Soc Nephrol. 2005;16:1811-8.
76. Oboh HA, Idogun ES. The assessment of plasma ascorbic acid, alpha tocopherol and albumin creatinine ratio in patients with chronic renal failure. Nig Q J Hosp Med. 2011;21:294-8.
77. Aminzadeh MA, Vaziri ND. Downregulation of the renal and hepatic hydrogen sulfide (H2S)-producing enzymes and capacity in chronic kidney disease. Nephrol Dial Transplant. 2012;27:498-504.
78. Takayama F, Tsutsui S, Horie M, Shimokata K, Niwa T. Glutathionyl hemoglobin in uremic patients undergoing hemodialysis and continuous ambulatory peritoneal dialysis. Kidney Int Suppl. 2001;78:S155-8.
79. Baylis C. Arginine, arginine analogs and nitric oxide production in chronic kidney disease. Nat Clin Pract Nephrol. 2006;2:209-20.
80. El-Mesallamy HO, Abdel Hamid SG, Gad MZ. Oxidative stress and asymmetric dimethylarginine are associated with cardiovascular complications in hemodialysis patients: improvements by L-arginine intake. Kidney Blood Press Res. 2008;31:189-95.
81. Pawlak K, Domaniewski T, Mysliwiec M, Pawlak D. Kynurenines and oxidative status are independently associated with thrombomodulin and von Willebrand factor levels in patients with end-stage renal disease. Thromb Res. 2009;124:452-7.
82. Pawlak K, Kowalewska A, Mysliwiec M, Pawlak D. Kynurenine and its metabolites--kynurenic acid and anthranilic acid are associated with soluble endothelial adhesion molecules and oxidative status in patients with chronic kidney disease. Am J Med Sci. 2009;338:293-300.
83. Pawlak K, Domaniewski T, Mysliwiec M, Pawlak D. The kynurenines are associated with oxidative stress, inflammation and the prevalence of cardiovascular disease in patients with end-stage renal disease. Atherosclerosis. 2009;204:309-14.
84. Pawlak K, Brzosko S, Mysliwiec M, Pawlak D. Kynurenine, quinolinic acid--the new factors linked to carotid atherosclerosis in patients with end-stage renal disease. Atherosclerosis. 2009;204:561-6.
85. Annuk M. Which marker is informative in characterizing the level of oxidative stress in ESRD patients? Nephron Clin Pract. 2004;98:c1-2.
86. Yu S, Paetau-Robinson I. Dietary supplements of vitamins E and C and beta-carotene reduce oxidative stress in cats with renal insufficiency. Vet Res Commun. 2006;30:403-13.
87. Baldi S, Innocenti M, Frascerra S, et al. Effects of hemodialysis and vitamin E supplementation on lowdensity lipoprotein oxidizability in end-stage renal failure. J Nephrol. 2013;26:549-55.
88. Islam KN, O’Byrne D, Devaraj S, Palmer B, Grundy SM, Jialal I. Alpha-tocopherol supplementation decreases the oxidative susceptibility of LDL in renal failure patients on dialysis therapy. Atherosclerosis. 2000;150:217-24.
89. Boaz M, Smetana S, Weinstein T, et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebocontrolled trial. Lancet. 2000;356:1213-8.
90. Korish AA, Arafah MM. Catechin combined with vitamins C and E ameliorates insulin resistance (IR) and atherosclerotic changes in aged rats with chronic renal failure (CRF). Arch Gerontol Geriatr. 2008;46:25-39.
91. Akiyama S, Inagaki M, Tsuji M, et al. Comparison of effect of vitamin E-coated dialyzer and oral vitamin E on hemodialysis-induced Cu/Zn-superoxide dismutase. Am J Nephrol. 2005;25:500-6.
92. Morimoto H, Nakao K, Fukuoka K, et al. Long-term use of vitamin E-coated polysulfone membrane reduces oxidative stress markers in haemodialysis patients. Nephrol Dial Transplant. 2005;20:2775-82.
93. Takouli L, Hadjiyannakos D, Metaxaki P, et al. Vitamin E-coated cellulose acetate dialysis membrane: long-term effect on inflammation and oxidative stress. Ren Fail. 2010;32:287-93.
94. Himmelfarb J, Phinney S, Ikizler TA, Kane J, McMonagle E, Miller G. Gamma-tocopherol and docosahexaenoic acid decrease inflammation in dialysis patients. J Ren Nutr. 2007;17:296-304.
95. Ramos LF, Kane J, McMonagle E, et al. Effects of combination tocopherols and alpha lipoic acid therapy on oxidative stress and inflammatory biomarkers in chronic kidney disease. J Ren Nutr. 2011;21:211-8.
96. Himmelfarb J, Ikizler TA, Ellis C, et al. Provision of antioxidant therapy in hemodialysis (PATH): a randomized clinical trial. J Am Soc Nephrol. 2014;25:623-33.
97. Washio K, Inagaki M, Tsuji M, et al. Oral vitamin C supplementation in hemodialysis patients and its effect on the plasma level of oxidized ascorbic acid and Cu/ Zn superoxide dismutase, an oxidative stress marker. Nephron Clin Pract. 2008;109:c49-54.
98. Ferretti G, Bacchetti T, Masciangelo S, Pallotta G. Lipid peroxidation in hemodialysis patients: effect of vitamin C supplementation. Clin Biochem. 2008;41:381-6.
99. Tarng DC, Liu TY, Huang TP. Protective effect of vitamin C on 8-hydroxy-2’-deoxyguanosine level in peripheral blood lymphocytes of chronic hemodialysis patients. Kidney Int. 2004;66:820-31.
100. Sato M, Matsumoto Y, Morita H, Takemura H, Shimoi K, Amano I. Effects of vitamin supplementation on microcirculatory disturbance in hemodialysis patients without peripheral arterial disease. Clin Nephrol. 2003;60:28-34.
101. Boudouris G, Verginadis, II, Simos YV, et al. Oxidative stress in patients treated with continuous ambulatory peritoneal dialysis (CAPD) and the significant role of vitamin C and E supplementation. Int Urol Nephrol. 2013;45:1137-44.
102. Fumeron C, Nguyen-Khoa T, Saltiel C, et al. Effects of oral vitamin C supplementation on oxidative stress and inflammation status in haemodialysis patients. Nephrol Dial Transplant. 2005;20:1874-9.
103. Ramos R, Martinez-Castelao A. Lipoperoxidation and hemodialysis. Metabolism. 2008;57:1369-74.
104. Bouzidi N, Mekki K, Boukaddoum A, Dida N, Kaddous A, Bouchenak M. Effects of omega-3 polyunsaturated fatty-acid supplementation on redox status in chronic renal failure patients with dyslipidemia. J Ren Nutr. 2010;20:321-8.
105. Tayyebi-Khosroshahi H, Houshyar J, Tabrizi A, Vatankhah AM, Razzagi Zonouz N, Dehghan-Hesari R. Effect of omega-3 fatty acid on oxidative stress in patients on hemodialysis. Iran J Kidney Dis. 2010;4:322-6.
106. Ivanovski O, Szumilak D, Nguyen-Khoa T, et al. The antioxidant N-acetylcysteine prevents accelerated atherosclerosis in uremic apolipoprotein E knockout mice. Kidney Int. 2005;67:2288-94.
107. Zachwieja J, Zaniew M, Bobkowski W, et al. Beneficial in vitro effect of N-acetyl-cysteine on oxidative stress and apoptosis. Pediatr Nephrol. 2005;20:725-31.
108. Zaniew M, Zachwieja J, Warzywoda A, Stefaniak E, Runowski D, Lewandowska-Stachowiak M. [Influence of vitamin E and N-acetylcysteine on intracellular oxidative stress in T lymphocytes in children treated with dialysis]. Wiad Lek. 2005;58 Suppl 1:58-65. Polish.
109. Bostom AG, Shemin D, Yoburn D, Fisher DH, Nadeau MR, Selhub J. Lack of effect of oral N-acetylcysteine on the acute dialysis-related lowering of total plasma homocysteine in hemodialysis patients. Atherosclerosis. 1996;120:241-4.
110. Hsu SP, Chiang CK, Yang SY, Chien CT. N-acetylcysteine for the management of anemia and oxidative stress in hemodialysis patients. Nephron Clin Pract. 2010;116:c207-16.
111. Nolin TD, Ouseph R, Himmelfarb J, McMenamin ME, Ward RA. Multiple-dose pharmacokinetics and pharmacodynamics of N-acetylcysteine in patients with end-stage renal disease. Clin J Am Soc Nephrol. 2010;5:1588-94.
112. Laviano A, Meguid MM, Guijarro A, et al. Antimyopathic effects of carnitine and nicotine. Curr Opin Clin Nutr Metab Care. 2006;9:442-8.
113. Fatouros IG, Douroudos I, Panagoutsos S, et al. Effects of L-carnitine on oxidative stress responses in patients with renal disease. Med Sci Sports Exerc. 2010;42:1809-18.
114. Pertosa G, Grandaliano G, Simone S, Soccio M, Schena FP. Inflammation and carnitine in hemodialysis patients. J Ren Nutr. 2005;15:8-12.
115. Sener G, Paskaloglu K, Satiroglu H, Alican I, Kacmaz A, Sakarcan A. L-carnitine ameliorates oxidative damage due to chronic renal failure in rats. J Cardiovasc Pharmacol. 2004;43:698-705.
116. Gokbel H, Atalay H, Okudan N, Solak Y, Belviranli M, Turk S. Coenzyme Q10 and its relation with oxidant and antioxidant system markers in patients with end-stage renal disease. Ren Fail. 2011;33:677-81.
117. Sakata T, Furuya R, Shimazu T, Odamaki M, Ohkawa S, Kumagai H. Coenzyme Q10 administration suppresses both oxidative and antioxidative markers in hemodialysis patients. Blood Purif. 2008;26:371-8.
118. Chiarello PG, Vannucchi MT, Moyses Neto M, Vannucchi H. Hyperhomocysteinemia and oxidative stress in hemodialysis: effects of supplementation with folic acid. Int J Vitam Nutr Res. 2003;73:431-8.
119. Sen U, Basu P, Abe OA, et al. Hydrogen sulfide ameliorates hyperhomocysteinemia-associated chronic renal failure. Am J Physiol Renal Physiol. 2009;297:F410-9.
120. Diepeveen SH, Verhoeven GW, Van Der Palen J, et al. Effects of atorvastatin and vitamin E on lipoproteins and oxidative stress in dialysis patients: a randomisedcontrolled trial. J Intern Med. 2005;257:438-45.
121. Dubois F, Belleville F. [Selenium: physiologic role and value in human pathology]. Pathol Biol (Paris). 1988;36:1017-25. French.
122. Zachara BA, Koterska D, Manitius J, et al. Selenium supplementation on plasma glutathione peroxidase activity in patients with end-stage chronic renal failure. Biol Trace Elem Res. 2004;97:15-30.
123. Zachara BA, Gromadzinska J, Zbrog Z, et al. Selenium supplementation to chronic kidney disease patients on hemodialysis does not induce the synthesis of plasma glutathione peroxidase. Acta Biochim Pol. 2009;56:183-7.
124. Temple KA, Smith AM, Cockram DB. Selenatesupplemented nutritional formula increases plasma selenium in hemodialysis patients. J Ren Nutr. 2000;10:16-23.
125. Bellisola G, Perona G, Galassini S, Moschini G, Guidi GC. Plasma selenium and glutathione peroxidase activities in individuals living in the Veneto region of Italy. J Trace Elem Electrolytes Health Dis. 1993;7:242-4.
126. Kiss I. [Importance of selenium homeostasis in chronic and end-stage kidney diseases]. Orv Hetil. 2013;154:1641-7. Hungarian.
127. Koenig JS, Fischer M, Bulant E, Tiran B, Elmadfa I, Druml W. Antioxidant status in patients on chronic hemodialysis therapy: impact of parenteral selenium supplementation. Wien Klin Wochenschr. 1997;109:13-9.
128. Zachara BA, Gromadzinska J, Palus J, et al. The effect of selenium supplementation in the prevention of DNA damage in white blood cells of hemodialyzed patients: a pilot study. Biol Trace Elem Res. 2011;142:274-83.
129. Adamowicz A, Trafikowska U, Trafikowska A, Zachara B, Manitius J. Effect of erythropoietin therapy and selenium supplementation on selected antioxidant parameters in blood of uremic patients on long-term hemodialysis. Med Sci Monit. 2002;8:202-5
130. Milly K, Wit L, Diskin C, Tulley R. Selenium in renal failure patients. Nephron. 1992;61:139-44.
131. Zwolinska D, Morawska Z, Dobracka A, Miler M, Makulska I, Krol Z. [Concentration of selected trace elements in serum and erythrocytes of children with chronic renal failure and am attempt at deficiency correction with animal blood preparation]. Wiad Lek. 1993;46:116-9. Polish.
132. Guo CH, Wang CL, Chen PC, Yang TC. Linkage of some trace elements, peripheral blood lymphocytes, inflammation, and oxidative stress in patients undergoing either hemodialysis or peritoneal dialysis. Perit Dial Int. 2011;31:583-91.
133. Guo CH, Chen PC, Hsu GS, Wang CL. Zinc supplementation alters plasma aluminum and selenium status of patients undergoing dialysis: a pilot study. Nutrients. 2013;5:1456-70.
134. Dvornik S, Cuk M, Racki S, Zaputovic L. Serum zinc concentrations in the maintenance hemodialysis patients. Coll Antropol. 2006;30:125-9.
135. Castilla P, Echarri R, Davalos A, et al. Concentrated red grape juice exerts antioxidant, hypolipidemic, and antiinflammatory effects in both hemodialysis patients and healthy subjects. Am J Clin Nutr. 2006;84:252-62.
136. Castilla P, Davalos A, Teruel JL, et al. Comparative effects of dietary supplementation with red grape juice and vitamin E on production of superoxide by circulating neutrophil NADPH oxidase in hemodialysis patients. Am J Clin Nutr. 2008;87:1053-61.
137. Priyadarshi S, Valentine B, Han C, et al. Effect of green tea extract on cardiac hypertrophy following 5/6 nephrectomy in the rat. Kidney Int. 2003;63:1785-90.
138. Roozbeh J, Shahriyari B, Akmali M, et al. Comparative effects of silymarin and vitamin E supplementation on oxidative stress markers, and hemoglobin levels among patients on hemodialysis. Ren Fail. 2011;33:118-23.
139. Shimoishi K, Anraku M, Kitamura K, et al. An oral adsorbent, AST-120 protects against the progression of oxidative stress by reducing the accumulation of indoxyl sulfate in the systemic circulation in renal failure. Pharm Res. 2007;24:1283-9.
140. Nakamura T, Sato E, Fujiwara N, et al. Oral adsorbent AST-120 ameliorates tubular injury in chronic renal failure patients by reducing proteinuria and oxidative stress generation. Metabolism. 2011;60:260-4.
141. Kasimay O, Sener G, Cakir B, et al. Estrogen protects against oxidative multiorgan damage in rats with chronic renal failure. Ren Fail. 2009;31:711-25.
142. Ienaga K, Mikami H, Yokozawa T. First indications demonstrating the preventive effects of NZ-419, a novel intrinsic antioxidant, on the initiation and/or progression of chronic renal failure in rats. Biol Pharm Bull. 2009;32:1204-8.